All In Biotech

Drug Trial Radar · NCT07653477

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

A Multicenter, Randomized, Open-Label, Semaglutide Injection-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With Metformin Alone or in Combination With Sulfonylurea/Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Therapy (UNIGUIDE-2)

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 956 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

956

Planned (sponsor's estimate)

Start

Sep 7, 2026

Primary completion

Feb 29, 2028

Study completion Feb 29, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide Injection after 40 weeks of continuous administration in study participants with Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control on oral antidiabetic medications.A total of 956 participants are planned to be enrolled, including the UBT251 Injection 2 mg group, 4 mg group, 6 mg group, and Semaglutide group,with an approximate study duration of 58 weeks per participant.

Conditions

  • Type 2 Diabetes

Interventions

  • UBT251 Injection 2.0 mg groupDrug

    UBT251 Injection subcutaneously once weekly

  • UBT251 Injection 4.0 mg groupDrug

    UBT251 Injection subcutaneously once weekly

  • UBT251 Injection 6.0 mg groupDrug

    UBT251 Injection subcutaneously once weekly

  • Semaglutide InjectionDrug

    Semaglutide Injection subcutaneously once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: Week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital,Fudan University

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.